NOTE 8  COMMITMENTS AND CONTINGENCIES License On February 1, 2018, Spinus entered into an Intellectual Property Licensing Agreement (the Licensing Agreement). The Company assumed the obligations under the Licensing Agreement and pledged the assets of Spinus as security. Pursuant to the terms of the Licensing Agreement, in consideration of $250,000 Spinus has the exclusive rights to certain patents and the non-exclusive rights to other patents. The patents surround mechanical or inflatable expandable interbody implant products. The $250,000 was due the earlier of (i) February 16, 2019 or (ii) 15 days subsequent to the Company completing a minimum of a $3,000,000 equity raise. The Company paid the $250,000 on November 20, 2018. The Company also will pay a royalty of 7% of net sales on any product sold utilizing any of the patents. There have not been any sales of the licensed products and accordingly, no royalties have been incurred. Consulting Agreements On August 31, 2018, we entered into an investor relations consulting agreement with Kingdom Building, Inc. (Kingdom) whereby Kingdom agreed to provide us with investor relations, public relations and financial media relations consulting services. The term of the agreement is for a period of 12 months. We may terminate the agreement after the initial six months on 60 days notice. We agreed to pay Kingdom $8,500 per month which amount is deferred until we complete a financing transaction with a minimum raise of $1,500,000 in gross proceeds. In addition, we issued Kingdom 650,000 shares of our unregistered common stock and reimburse them for certain out of pocket expenses. The Company valued the common stock at $325,000, based on the market price of the common stock on the date of the agreement, to be amortized over the one-year term. For the three months ended March 31, 2019, the Company amortized $81,250 as stock- based compensation expense. As of March 31, 2019, there remains $135,417 of deferred stock compensation on the consolidated balance sheet, to be amortized over the remaining contract term. On October 19, 2018, the Company entered into a consulting agreement (the Consulting Agreement) with Draper Inc., a Nevada corporation (Draper). Pursuant to the Consulting Agreement the Company engaged Draper as an independent consultant and Draper agreed to provide the Company with consulting services. In exchange for the services to be provided by Draper pursuant to the Consulting Agreement, the Company agreed to issue Draper a total of 1,800,000 unregistered shares of the Companys $0.001 par value per share, common stock, with 450,000 shares issued upon execution of the Consulting Agreement, and with 150,000 shares be issued and delivered each month at the beginning of the fourth month to the beginning of the twelve month, until the total amount of shares is issued. Either party can terminate the Consulting Agreement by giving 30 days written notice to the other party. The Company valued the initial 450,000 shares at $225,000, based on the market price of the common stock on the date of the agreement, to be amortized over the first three months of the contract. For the three months ended March 31, 2019, the Company amortized $52,500 as stock-based compensation expense. For the three months ended March 31, 2019, the Company recorded 450,000 shares of common stock to be issued, and valued the shares at $344,970, based on the market price of the common stock on the date of the shares being earned. For the three months ended March 31, 2019, the company amortized $260,470 as stock-based compensation expense. As of March 31, 2019, there remains $84,500 of deferred stock compensation on the condensed consolidated balance sheet, to be amortized in April, 2019. On February 27, 2019, the Company entered into a Mutual Agreement of Understanding (the Agreement) with Eric Siu pursuant to which the Company agreed to approve and ratify all of Mr. Suis and his related parties efforts at pursuing medical device sales and manufacturing in greater China. Additionally, pursuant to the Agreement, the Company and Mr. Siu agreed to confirm and settle amounts owed to Mr. Siu and related parties by the Company upon the completion of the audit of the Company as of December 31, 2018. On March 5, 2019, Eric Sui resigned from his position as a member of the Board. On March 4, 2019, the Company entered into a Separation Agreement (the Separation Agreement) with Salman J. Chaudhry, pursuant to which Mr. Chaudry resigned immediately from his positions as the CCO and Secretary of the Company and as a member of the Board and from all positions with the Company effective immediately and pursuant to which the Company agreed to pay Mr. Chaudry $227,200 (the Outstanding Fees) in certain increments as set forth in the Separation Agreement. Mr. Chaudrys resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. During the three months ended March 31, 2019, the Company paid Mr. Chaudhry $16,086, and the balance owed is $211,115. On March 24, 2019, the Company and Newbridge Securities Corporation (Newbridge) entered into an Investment Banking Engagement Agreement (the Agreement). Under the terms of the Agreement, Newbridge will provide investment banking and financial advisory services to the Company, including, but not limited to assisting the Company with an up-listing process to a national exchange in the United States, introducing the Company to other investment banking firms focused on servicing emerging growth companies; rendering advice related to capital structures, capital market opportunities, evaluating potential capital raise transactions and assisting the Company to develop growth optimization strategies. The term of the Agreement is 12 months from the date of the Agreement, however either party may terminate the Agreement anytime upon 15 days written notice. As compensation for its services under the Agreement, Newbridge and its assignees received 171,400 shares of the Companys common stock. The Agreement contains customary terms relating to payment of expenses, indemnification and other matters. The Agreement also includes customary representations, warranties and covenants by the Company. The Company valued the shares at $77,130, based on the market price of the common stock on the date of the agreement, to be amortized over the one-year term of the contract. For the three months ended March 31, 2019, the Company amortized $1,500 as stock-based compensation expense. As of March 31, 2019, there remains $75,630 of deferred stock compensation on the condensed consolidated balance sheet, to be amortized over the remaining term of the agreement.